中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

26 records (took 0.025 seconds)

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    11.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180161396A1

    公开(公告)日：2018-06-14

    申请号：US15834633

    申请日：2017-12-07

    Applicant: immatics biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

    IPC: A61K38/17 ,  A61K35/17 ,  C07K14/725 ,  C12N15/85 ,  A61P35/00

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    12.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180051080A1

    公开(公告)日：2018-02-22

    申请号：US15677651

    申请日：2017-08-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    15.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 有权

    公开(公告)号：US20210388079A1

    公开(公告)日：2021-12-16

    申请号：US17397656

    申请日：2021-08-09

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/26 ,  C07K14/725 ,  C07K14/81 ,  C07K16/28 ,  C07K16/38 ,  C12N15/85 ,  C12N5/0783

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    16.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20190284276A1

    公开(公告)日：2019-09-19

    申请号：US16402829

    申请日：2019-05-03

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  C07K16/18 ,  C07K14/725 ,  C07K14/78

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
    17.
    发明申请
    TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 审中-公开

    公开(公告)号：US20190269769A1

    公开(公告)日：2019-09-05

    申请号：US16413939

    申请日：2019-05-16

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Dominik MAURER ,  Leonie ALTEN ,  Sebastian BUNK

    IPC: A61K39/00 ,  C07K14/725 ,  G01N33/574 ,  A61K45/06 ,  C07K14/74

    Abstract: The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    19.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20190002556A1

    公开(公告)日：2019-01-03

    申请号：US16023731

    申请日：2018-06-29

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/26 ,  C12N5/0783 ,  C12N15/85

    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    20.
    发明申请
    NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME 审中-公开

    公开(公告)号：US20180319884A1

    公开(公告)日：2018-11-08

    申请号：US16035300

    申请日：2018-07-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Leonie ALTEN ,  Dominik MAURER ,  Steffen WALTER ,  Sebastian BUNK

    IPC: C07K16/28 ,  C07K14/78 ,  C07K14/725 ,  A61P35/00 ,  C07K16/18 ,  A61K39/00

    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Patent Agency Ranking